Menu

Cell Signaling and Metabolism: Bridging a Gap in Cancer Therapies

The Scientist is bringing together a panel of experts to discuss their research into an exciting and recently acknowledged hallmark of cancer.

Jun 29, 2018
The Scientist Creative Services Team

 

FREE Webinar

Wednesday, October 24, 2018
2:30-4:00 PM Eastern Time
Register Now

That cancer cells display an altered metabolism has been known for almost a century, but the cell-signaling mechanisms responsible for this phenomenon are just beginning to be understood, with some drugs targeting key regulators of both cell metabolism and tumor progression. The repurposing of old drugs for the activation and/or inhibition of proteins at the center of the cell-signaling and metabolism web has been a popular strategy for addressing these challenges. Drugs like metformin, chloroquine, and various statins are just a few examples of those in clinical trials. They offer a cost-effective advantage in addition to an already-established pharmacokinetic and pharmacodynamic profile. To further explore cell metabolism as a novel avenue of drug discovery based on already-established cell signaling mechanisms essential for tumor progression, The Scientist is bringing together a panel of experts to discuss their research into this exciting and recently acknowledged hallmark of cancer. 

Topics to be covered:

  • Metabolic symbioses in tumor microenvironments
  • Uncovering metabolic bottlenecks in genetic subtypes of lung cancer

Register Now

Meet the Speakers:

M. Celeste Simon, PhD
Scientific Director and Investigator, Abramson Family Cancer Research Institute
Associate Director-Shared Resources, Abramson Cancer Center
Rubenstein Professor, Department of Cell and Developmental Biology
University of Pennsylvania Perelman School of Medicine

Thales Papagiannakopoulos, PhD
Assistant Professor
Department of Pathology
NYU School of Medicine

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.